The simplified DUTCH Report has arrived, and current DUTCH Providers are eligible for up to 5 DUTCH Complete or DUTCH Plus test kits for 50% off. Learn more and claim this offer!
RESEARCH

Sensitivity, Specificity, and Predictive Value of Urinary Androgen Metabolites for the Diagnosis of Polycystic Ovary Syndrome

ASRM | 2022

Mark Newman, MS,

Doreen Saltiel, MD,

Bryan P. Mayfield, PharmD,

and Frank Z. Stanczyk



Mark Newman, MS, Doreen Saltiel, MD, JD, Bryan P. Mayfield, PharmD, and Frank Z. Stanczyk, PhD
DOI: https://doi.org/10.1016/j.fertnstert.2022.08.594


Objective

The objective of this study was to determine if urinary androgen metabolite concentrations measured using an at-home dried urine sampling method and an accompanying gas chromatography-tandem mass spectrometry (GC-MS/MS) assay could be used to confirm or rule out polycystic ovary syndrome (PCOS).


Materials and Methods

This was a retrospective observational cohort study conducted using a database containing 144,561 laboratory accessions that were submitted between January 1, 2016 and December 9, 2019 by 129,883 patients. These patients collected urine samples on filter paper at home and sent the collections to the laboratory to be processed. Urinary concentrations of androsterone, dehydroepiandrosterone sulfate (DHEA-S), epitestosterone, etiocholanolone, testosterone, 5α-androstanediol, 5β-androstanediol, and 5α-dihydrotestosterone (DHT) were measured. The database included a total of 2050 patients with a reported diagnosis of PCOS and 27488 patients who did not report a PCOS diagnosis. A "urinary androgen index" was created comprising all measured androgen metabolites. Mixed models were then created to determine sensitivity, specificity, and predictive values of the components of this urinary androgen index.


Results

Mixed models determined that for patients with a measured urinary androgen index greater than or equal to 4 (4 or more androgen metabolites above the reference range) the sensitivity was 0.44, the specificity was 0.78, the positive predictive value was 0.13, and the negative predictive value was 0.95. For patients with a measured epitestosterone, etiocholanolone, or testosterone above the reference range the sensitivity was 0.70, the specificity was 0.53, the positive predictive value was 0.10, and the negative predictive value was 0.96. For patients with a measured urinary testosterone higher than the 75th percentile of the reference range, the sensitivity was 0.47, the specificity was 0.76, the positive predictive value was 0.13, and the negative predictive value was 0.95.


Conclusions

Urinary androgen metabolites measured using a dried urine sample and a validated GC-MS/MS assay demonstrated low positive predictive values, but high negative predictive values for PCOS suggesting that these measures may be of use in ruling out PCOS.


Impact Statement

In this large general population study, a dried urine sampling method measuring androgen metabolites demonstrated the potential to be effective at ruling out PCOS. This method may represent a new, convenient, at-home, non-invasive tool for clinicians and researchers to use in settings where barriers exist to in-person patient evaluation or ultrasonography. When combined with additional information available from urine sampling, this tool may provide a comprehensive panel of results to inform both clinical investigation and decision making.


View Full Study